The Latin America, Middle East and Africa Circulating Tumor Cell Market is expected to witness market growth of 15.1% CAGR during the forecast period (2024-2031).
The Brazil market dominated the LAMEA Circulating Tumor Cell Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $562.9 million by 2031. The Argentina market is showcasing a CAGR of 15.7% during 2024-2031. Additionally, the UAE market would register a CAGR of 14% during 2024-2031.
One of the most critical roles of CTCs is assessing cancers' metastatic potential. The presence of CTCs in the bloodstream is often indicative of metastasis, and their number correlates with tumor burden and patient prognosis.
Moreover, monitoring CTCs over time allows oncologists to track cancer progression and make more informed decisions about treatment plans. The dynamic tracking of CTC levels can provide insights into how a cancer responds to therapy, enabling adjustments to treatment regimens for improved outcomes.
With its significant contribution to the Gulf Cooperation Council’s (GCC) healthcare spending (accounting for 60% of the region’s total), Saudi Arabia continues to prioritize healthcare investment. In 2023, the Saudi government allocated USD 50.4 billion (16.96% of its 2023 budget) for healthcare and social development. This robust investment underpins the country’s commitment to improving healthcare services, with cancer treatment being one of the key areas of focus. The country’s emphasis on advanced medical research and a growing demand for personalized and precise treatments will likely drive the need for CTC diagnostics.
The Brazil market dominated the LAMEA Circulating Tumor Cell Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $562.9 million by 2031. The Argentina market is showcasing a CAGR of 15.7% during 2024-2031. Additionally, the UAE market would register a CAGR of 14% during 2024-2031.
One of the most critical roles of CTCs is assessing cancers' metastatic potential. The presence of CTCs in the bloodstream is often indicative of metastasis, and their number correlates with tumor burden and patient prognosis.
Moreover, monitoring CTCs over time allows oncologists to track cancer progression and make more informed decisions about treatment plans. The dynamic tracking of CTC levels can provide insights into how a cancer responds to therapy, enabling adjustments to treatment regimens for improved outcomes.
With its significant contribution to the Gulf Cooperation Council’s (GCC) healthcare spending (accounting for 60% of the region’s total), Saudi Arabia continues to prioritize healthcare investment. In 2023, the Saudi government allocated USD 50.4 billion (16.96% of its 2023 budget) for healthcare and social development. This robust investment underpins the country’s commitment to improving healthcare services, with cancer treatment being one of the key areas of focus. The country’s emphasis on advanced medical research and a growing demand for personalized and precise treatments will likely drive the need for CTC diagnostics.
List of Key Companies Profiled
- Qiagen N.V
- Greiner Bio-One International GmbH
- Sysmex Corporation
- Miltenyi Biotech B.V & Co kg
- Bio-Techne Corporation
- Ikonisys, Inc.
- Menarini Silicon Biosystems SpA
- LungLife AI Inc.
- Aviva Systems Biology Corporationa
- ScreenCell
Market Report Segmentation
By Product
- Kits & Reagents
- Devices
- Blood Collection Tubes
By End User
- Research and Academic Institutes
- Hospital & Clinics
- Diagnostic Centers
By Specimen
- Blood
- Bone Marrow
- Other Specimen
By Technology
- CTC Detection & Enrichment Methods
- CTC Analysis
- CTC Direct Detection
By Application
- Research, Clinical
- Drug/Therapy Development
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA Circulating Tumor Cell Market by Product
Chapter 5. LAMEA Circulating Tumor Cell Market by End User
Chapter 6. LAMEA Circulating Tumor Cell Market by Specimen
Chapter 7. LAMEA Circulating Tumor Cell Market by Technology
Chapter 8. LAMEA Circulating Tumor Cell Market by Application
Chapter 9. LAMEA Circulating Tumor Cell Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Qiagen N.V
- Greiner Bio-One International GmbH
- Sysmex Corporation
- Miltenyi Biotech B.V & Co kg
- Bio-Techne Corporation
- Ikonisys, Inc.
- Menarini Silicon Biosystems SpA
- LungLife AI Inc.
- Aviva Systems Biology Corporation
- ScreenCell
Methodology
LOADING...
